Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Women's Health and Genetics/Laboratory Corporation of America, |
RCV001264503 | SCV001442689 | benign | not specified | 2020-10-13 | criteria provided, single submitter | clinical testing | Variant summary: CD40 c.647-3dupT alters a nucleotide located close to a canonical splice site and therefore could affect mRNA splicing, leading to a significantly altered protein sequence. 4/4 computational tools predict no significant impact on normal splicing. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 0.083 in 89320 control chromosomes in the gnomAD database, including 639 homozygotes. The observed variant frequency is approximately 528-fold of the estimated maximal expected allele frequency for a pathogenic variant in CD40 causing Hyper IgM Syndrome Type 3 phenotype (0.00016), strongly suggesting that the variant is benign. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified as benign. |
Genome- |
RCV001420684 | SCV001623025 | benign | Hyper-IgM syndrome type 3 | 2021-05-18 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001655709 | SCV001864624 | benign | not provided | 2021-06-19 | criteria provided, single submitter | clinical testing |